The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 30, 2026

Conditions

Uterine Fibroid

Interventions

DRUG

Ryeqo treatment

Ryeqo treatment will be administered and hemostasis markers will be measured at T0 and T1

Trial Locations (1)

RECRUITING

Hôpitaux Universitaires de Genève, Geneva

All Listed Sponsors

lead

University Hospital, Geneva

OTHER